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Alpha-synuclein: from secretion to dysfunction
and death
O Marques1 and TF Outeiro*,1,2,3
The aggregation, deposition, and dysfunction of alpha-synuclein (aSyn) are common events in neurodegenerative disorders
known as synucleinopathies. These include Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy.
A growing body of knowledge on the biology of aSyn is emerging and enabling novel hypotheses to be tested. In particular,
the hypothesis that aSyn is secreted from neurons, thus contributing to the spreading of pathology not only in the brain but also
in other organs, is gaining momentum. Nevertheless, the precise mechanism(s) of secretion, as well as the consequences of
extracellular aSyn species for neighboring cells are still unclear. Here, we review the current literature and integrate existing data
in order to propose possible mechanisms of secretion, cell dysfunction, and death. Ultimately, the complete understanding of
these processes might open novel avenues for the development of new therapeutic strategies.
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Facts
 Alpha-synuclein is associated with both familial and
idiopathic cases of Parkinson’s disease.
 The precise function of alpha-synuclein remains equivocal.
 Alpha-synuclein misfolds and forms protein aggregates in
Parkinson’s disease and in various in vitro and in vivo
models of synucleinopathies.
 Alpha-synuclein has been detected in human and mouse
CSF and in the media of cultured cells.
Open Questions
 Is alpha-synuclein normally secreted from cells or is it
released from dying/damaged cells? How is it secreted?
 What are the effects of secreted forms of alpha-synuclein?
 What is the toxic genus of alpha-synuclein?
 Is the spreading of alpha-synuclein pathology a prion-like
phenomenon?
Alpha-synuclein and Synucleinopathies
Alpha-synuclein (aSyn) is a 140 amino-acid protein that was
originally identified in association with synaptic vesicles in the
presynaptic nerve terminal1 and has been shown to interact
with membranes both in vitro and in vivo.2–4 It is highly
abundant in the brain and also present in other tissues,
including red blood cells.5–8 aSyn is a member of a protein
family of synucleins, together with beta (b)- and gamma (g)-
synuclein. These proteins share a characteristic consensus
sequence (KTKEGV) that is repeated about six times at the
N-terminal part of the protein. b-synuclein shares the closest
homology (90% homology in the N-terminus and 33%
homology in the C-terminus) with aSyn.5
Point mutations in the SNCA gene, encoding for aSyn, and
multiplications of the SNCA locus have been identified in
families with autosomal-dominant forms of Parkinson’s dis-
ease (PD).9 Genome-wide association studies linked single-
nucleotide polymorphisms in the SNCA gene with increased
susceptibility to sporadic PD.10 Moreover, SNCA gene poly-
morphisms have also been associated with increased risk of
multiple system atrophy (MSA).11
In PD, aSyn is found as a major component of Lewy bodies
and Lewy neurites, the hallmark protein inclusions made up
primarily of insoluble and fibrillar aSyn protein.12 aSyn also
accumulates in dementia with Lewy bodies (DLB) and MSA.13
In MSA, aSyn is found predominantly within oligodendrocytes
as cytoplasmic inclusions.14 These disorders share the
accumulation of aSyn aggregates as a pathological feature
and are collectively known as synucleinopathies. Additionally,
aSyn was also identified as a component of amyloid from brain
tissues of Alzheimer’s disease (AD) patients.15
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The presence of a hydrophobic 12 amino-acid sequence in
the central part of the protein is required for the oligomeriza-
tion and fibrillization of aSyn.16 Deletion or disruption of this
domain blocks the capacity of aSyn to form amyloid fibrils. The
process of aSyn aggregation (Figure 1) has been studied in
detail in an attempt to identify the toxic species responsible for
neuronal dysfunction and death. However, it is still unclear
what is/are the toxic forms of the protein. There is evidence
showing that inhibition of aSyn aggregation process is
associated with a decrease of aSyn toxicity.17,18 However,
similarly to the case of amyloid-beta (Ab) plaques in AD, it was
suggested that the fibrillar forms of aSyn might not represent
the most toxic aSyn species. Instead, pre-fibrillar, soluble
oligomeric species (comprising multiple aSyn molecules) are
now suggested to be the main toxic aSyn species, with
amyloid aggregates possibly serving as a reservoir for these
oligomeric species (Figure 1). In vitro studies showed that the
acceleration of oligomerisation, and not fibrilization, is the
distinctive shared property of the A53T and A30P aSyn
mutations linked to early-onset PD.19 The neurotoxic effects
of aSyn oligomers were also studied in vivo, using animal
models of synucleinopathies. In these studies, aSyn mutant
variants that promote oligomer formation were designed
and tested for toxicity in vivo. In one of these studies, over-
expression of aSyn variants with impaired fibril formation
ability caused increased toxicity in C. elegans and Drosophila
models. Furthermore, the increasing inability of the mutants to
form fibrils was directly correlated with toxicity and neurode-
generation.20 In another study, aSyn variants that were shown
to promote oligomer formation caused most prominent
dopaminergic cell death upon lentiviral injection into rat
substantia nigra (SN).21 Together, these studies provide
evidence for the importance of soluble oligomers as the
prominent toxic species in synucleinopathies, although the
precise size and type of the toxic oligomeric species remains
to be determined.
Recently, it was hypothesized that PD, as well as other
neurodegenerative disorders associated with protein misfold-
ing and aggregation, might be a prion-like disease where
pathological forms of aSyn spread throughout the brain.
In particular, the spreading of aSyn pathology could contribute
to the progression of neurodegeneration and clinical symp-
toms.22–24 Nevertheless, the molecular determinants under-
lying aSyn secretion, extracellular effects and transmission of
pathology are still unclear.
aSyn Function in Vesicle Trafficking
Accumulating evidence from studies involving different model
organisms, including yeast, worm, fly, and mammalian PD
models, shows an association between aSyn and defects in
vesicle trafficking.
aSyn was shown to induce aggregation of several yeast
Rab GTPase proteins and this aggregation was more
pronounced in yeast mutants that produce high levels of
acidic phospholipids.25 Furthermore, aSyn overexpression in
yeast causes cytoplasmic lipid droplet and vesicle accumula-
tion. This effect is associated with an aSyn-induced block
of ER-to-Golgi trafficking.26–28 Importantly, results from a
genetic screen in yeast identified modifiers of ER-to-Golgi
trafficking block as the most prominent suppressors of
aSyn toxicity.27 The Rab GTPase Ypt1p (orthologue of the
mammalian Rab1) was among the strongest suppressors,
restoring normal ER-to-Golgi complex trafficking and aSyn
localization to the plasma membrane.27 The protective
effect of Rab1 against aSyn toxicity was further verified in
rat primary midbrain neuronal cultures and in a Drosophila
and a C. elegans model of PD, where Rab1 overexpression
significantly reduced dopamine (DA) neuron cell death.27
An inhibitory effect of aSyn on ER-to-Golgi complex
trafficking was verified also in mammalian kidney and
neuroendocrine cells, with the A53T aSyn mutant causing
stronger inhibition then the wild-type form.29 The aSyn-elicited
trafficking defect can be rescued by the co-overexpression of
Ykt6p, a vesicle-associated SNARE that promotes vesicle
fusion, and has been amongst the suppressors of aSyn
toxicity previously identified in yeast.27,29
The mechanism of the aSyn-induced trafficking block was
further addressed in a recent study showing that in neuronal
cells, aSyn co-localizes and interacts with prenylated Rab
acceptor protein 1 (PRA1).30 PRA1 is conserved from yeast
to human and localizes predominantly in the Golgi and
late endosomes.31–33 It was shown to interact with multiple
prenylated Rab GTPases and regulate their recycling through
inhibiting the removal of Rab from the membrane by GDP
dissociation inhibitors.34 In addition to the previously
described accumulation of cytoplasmatic vesicles upon aSyn
overexpression, these vesicles localize in the periphery of the
cytosol when aSyn is co-expressed together with PRA1.30
These results suggest a synergistic action of aSyn and PRA1
in interfering with vesicle trafficking and recycling.
In addition, aSyn was recently shown to induce vulnerability
to perturbations in retrograde endosome–Golgi transport
pathway in a yeast model.25
Together these studies suggest that aSyn causes defects in
multiple vesicle trafficking steps.
Effects of aSyn on Neuronal Function and Synaptic
Transmission
Although the physiological function of aSyn is not fully
understood, there is evidence suggesting that aSyn has a
role in neurotransmitter release35–38 and in the maintenance
of the reserve pool of synaptic vesicles in primary hippocam-
pal neurons.
Mice lacking the synaptic co-chaperone cysteine-string
protein alpha (CSPa) present progressive neurodegeneration
and impairment in synaptic function. Interestingly, transgenic
expression of aSyn rescued neurodegeneration and motor
impairment resulting from CSPa deficiency. Moreover, aSyn
Figure 1 Schematic representation of the aSyn aggregation process.
Monomeric forms of aSyn associate to form dimers and oligomers that grow into
protofibrils and, finally, form mature fibrillar structures
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was able to reverse the SNARE-complex assembly impair-
ment observed in the CSPa knockout mice.36 These data
indicate a physiological neuroprotective function of aSyn at
the synapse.
Recently, a direct interaction between aSyn and SNARES
was demonstrated.39 aSyn was found to bind the N-terminus
of SNARE protein synaptobrevin-2 directly by its C-terminus.
This study also brought additional evidence that aSyn enhances
SNARE-complex assembly both in vitro and in vivo.39 Loss of
synuclein function leads to an age-dependent impairment of
SNARE-complex assembly and loss of neuronal function as
shown in alpha-, b- and g-synuclein triple knockout mice.40
However, another study suggested an indirect inhibitory
effect of aSyn on SNARE-complex assembly through seq-
uestering of arachidonic acid. Arachidonic acid was shown
to stimulate SNARE-complex formation and exocytosis and
these effects were negatively regulated by aSyn both in vitro
and in vivo.41
Together, these studies suggest a physiological function
of aSyn at the synapse in modulating SNARE-complex
assembly.
The role of aSyn in neurotransmitter release is mainly
based on its regulation of synaptic vesicle recycling. aSyn
knockout mice display altered DA release in response to
paired stimuli, reduction in striatal DA and an attenuation of
DA locomotor response to amphetamine.42 Another in vivo
study showed that lack of aSyn leads to a permanent increase
of the vesicle refilling rate in the DA readily releasable pool,
maintaining stable DA release during stimulation in contrast
to decline of DA release observed in normal conditions.43
Together, these findings suggest that aSyn is an activity-
dependent, negative regulator of DA neurotransmission.
Moreover, aSyn has also been shown to regulate synaptic
glutamate release. Electrophysiology studies in brains from
aSyn knockout mice suggest that lack of aSyn impairs
mobilization of glutamate from the reserve pool.44
Studies in animal models of PD pathology implicate aSyn in
functional synaptic deficits. In a transgenic mouse model
overexpressing A30P mutant aSyn, a reduction of locomotor
activity accompanied by a reduced size of the DA storage pool
was observed.45 In the striatum of a transgenic mouse model
expressing truncated human aSyn, synaptic accumulation of
aSyn was accompanied by an age-dependent redistribution of
the synaptic SNARE proteins as well as by reduction in DA
release.46 This redistribution of SNAREs is also observed
in PD brain samples. In cultured neurons from another PD
mouse model, aSyn overexpression leads to loss of several
presynaptic proteins and neurotransmitter release deficits.47
A modest overexpression of aSyn that does not lead to overt
toxicity causes significant inhibition of neurotransmitter
release through inhibition of vesicle reclustering after endo-
cytosis.48 These results indicate that increased levels of aSyn
lead to a defect in synaptic vesicle recycling that precedes
detectable neuropathology.
Imaging studies in patients also point to synaptic dysfunc-
tion and neurotransmitter deficiencies in synucleinopathies
including PD and DLB.49 Recently, small aSyn detergent-
insoluble aggregates with presynaptic localization were
detected abundantly in patients with DLB, together with
significant synaptic pathology with almost complete loss of
dendritic spines at the postsynaptic area.50,51 It has been
suggested that it is the presynaptic aSyn aggregation-linked
synaptic dysfunction, rather than cell death, that leads to
neurodegeneration in DLB and PD.51
Recently, the impact of different aSyn species (monomers,
oligomers, and fibrils) on synaptic transmission was explored.
Interestingly, oligomeric forms of aSyn were shown to
increase synaptic transmission and to impair long-term
potentiation,52 a paradigm that mimics the process of
memory formation. The effects of aSyn were mediated
by NMDA receptor activation, in similarity to what is also
known for Ab oligomers (Diogenes and Outeiro, personal
communication).
Altogether, the effects of aSyn on neuronal function are
emerging and will provide important insight into the molecular
basis of PD and other synucleinopathies.
Secretion of aSyn and Disease Propagation
The absence of a secretory signal peptide sequence in aSyn
suggested it might be purely an intracellular protein and its
pathological function was, therefore, studied in a cell
autonomous context. However, this view was challenged by
the presence of aSyn in biological fluids such as cerebrospinal
fluid (CSF) and blood plasma of both PD and normal
subjects.53–55 Recently, aSyn release mechanisms as well
as possible functions of extracellular aSyn have been
intensively studied.
aSyn was shown to be secreted into the culture medium in
various cell lines overexpressing aSyn.53,56,57 Moreover,
secretion of endogenous aSyn from rat embryonic cortical
neurons was also demonstrated.57 Both monomeric and
aggregated forms of aSyn were found to be secreted
(Figure 2).57,58
Figure 2 Proposed mechanisms of aSyn secretion. aSyn can be secreted both
in its monomeric or aggregated forms by non-classical exocytic or endocytic
pathways. aSyn can be directly integrated into secretory vesicles and subsequently
released by exocytosis (1). Alternatively, aSyn can be translocated to early endosomes.
From early endosomes, aSyn protein can either be released to the extracellular space
through the recycling endosome (2) or incorporated to intraluminal vesicles of
multivesicular bodies (MBV). MVB cargo including aSyn can be directed to
degradation by fusion with lysosomes or to secretion by fusion with the plasma
membrane and release of exosomal vesicles (3). TGN¼ trans-Golgi network
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The mechanisms of aSyn secretion are not fully understood,
but there is evidence showing that aSyn can be secreted
by non-classical, ER/Golgi-independent protein export path-
way (Figure 2).57 Upon overexpression in SH-SY5Y cells,
aSyn localizes in large dense core vesicles. Interestingly,
it was shown that this intravesicular fraction of aSyn is more
prone to aggregation compared with cytosolic aSyn protein.57
In another study, DA was shown to induce aSyn aggregation
in the vesicle fraction and to increase aSyn secretion levels.59
It has also been suggested that the release of aSyn is
upregulated under cellular stress conditions that cause
accumulation of misfolded/damaged proteins.60
Additionally, a fraction of aSyn was shown to be secreted in
association with exosomes by a calcium-dependent mechan-
ism (Figure 2)61 and exosomal aSyn release was found to
be increased upon lysosomal dysfunction.62 However, a very
recent study reports no enrichment of aSyn in exosomal pellet
of neuronal cells overexpressing aSyn as well as an absence
of aSyn-positive signal in exosomal fraction derived from CSF
of PD patients and control subjects.63 This study further
shows that in neuronal cells aSyn is present in endosomal
compartments (Figure 2), and that aSyn secretion and
lysosomal targeting is regulated by vacuolar protein sorting
4. Moreover, it was suggested that the recycling pathway
regulated by Rab11 has functional relevance in aSyn
secretion (Figure 2).63
In recent years, extracellular aSyn has received a lot of
scientific attention due to its potential role in disease initiation
and progression. Considering the progressive nature of
neurodegenerative disorders as well as the defined, step-
wise spreading of Lewy body pathology in PD,22 the idea of
extracellular aSyn as a pathogenic ‘prion-like’ agent is
extremely appealing. This scenario is strengthened by
observations describing the presence of aSyn-positive
Lewy-body-like inclusions in long-term mesencephalic trans-
plants in PD patients.23,64 These findings suggest host-to-
graft propagation of aSyn-associated pathology. Subsequent
in vitro experiments showed inter-neuronal transmission of
aSyn (Figure 3).58,65 Moreover, the host-to-graft transmission
of aSyn has also been observed in vivo in aSyn transgenic
mouse models.24,65 This transmission process seems to rely
on endocytic uptake of aSyn by the recipient neurons.24,66
All of these findings indicate that aSyn can be both secreted
and transmitted between neuronal cells. Moreover, there is
evidence suggesting that aSyn secretion is stimulated by
cellular stress conditions including lysosomal dysfunction.
aSyn-induced Neuroinflammation and Cell Death
Although many studies showed secretion and cell-to-cell
transmission of aSyn, this phenomenon might not, per se,
be sufficient to explain the spread of aSyn Lewy-body-like
pathology and progressive neurodegeneration observed in
PD. There is additional evidence, however, that aSyn can act
as a nucleation/seeding agent for aggregation and can affect
the viability of the recipient neurons (Figure 3).
Exogenous aSyn fibrils were shown to seed the formation of
Lewy-body-like intracellular inclusions in cultured cells.67
Furthermore, there is evidence of inclusion formation via
aSyn cell-to-cell transmission both in cell co-cultures and
in vivo in grafted cells (Figure 3).24,65 Importantly, in addition
to seeding aSyn aggregation, neuron-derived extracellular
aSyn triggered apoptotic process in recipient neurons.65
The neurotoxic effect of extracellular aSyn oligomeric
species was addressed in several studies. Recombinant
aSyn oligomers can be taken up by neurons in culture and
trigger cell death.68,69 Furthermore, aSyn oligomers secreted
from neuronal cells were also shown to induce toxicity in
recipient neurons,58 an effect that was inhibited by Hsp70.
Moreover, treatment of the conditioned media containing
neuron-derived aSyn with oligomer-interfering compounds
rescued the recipient neuronal cells from toxicity.61 Together,
these studies indicate an important role of extracellular aSyn
in the progression of PD-linked pathological processes,
propagation of inclusion bodies and neurodegeneration.
The importance of extracellular aSyn in PD pathology is
further supported by the role of aSyn in triggering neuroin-
flammatory glial responses. Several studies indicate that an
inflammatory process in the SN, characterized by the
presence of activated microglia and the secretion of pro-
inflammatory and neurotoxic factors, may contribute to either
initiation and/or aggravation of neuronal degeneration.70–72
Studies of biological fluids from PD patients further support a
role for neuroinflammatory processes in PD, as increased
levels of pro-inflammatory cytokines such as interleukin-1 b
(IL1-b), interleukin-2 (IL-2), interleukin-6 (IL-6) or tumor
necrosis factor-alpha (TNF-a) were found in CSF or serum
of PD patients.73–75
Various other studies focused on the investigation of
the extracellular effects of aSyn on glial cell activation
(Figure 3).76–80 Upon aSyn exposure in vitro, microglia cells
produce increased levels of NO, TNF-a and IL1-b77,78. The
A30P and E46K mutants of aSyn were shown to elicit stronger
pro-inflammatory and immunoregulatory responses when
Figure 3 The role of extracellular aSyn in neuroinflammation, neurotoxicity, and
spread of pathology. aSyn can be actively secreted or released by dying neurons to
the extracellular space. Extracellular aSyn can then activate surrounding astrocytes
and microglia, eliciting glial pro-inflammatory activity. Upon activation microglia
produce pro-inflammatory cytokines, nitric oxide, and reactive oxygen species,
which may be toxic to neurons. aSyn can be directly transferred between neurons,
leading to propagation of aSyn aggregation process and compromising the viability
of the recipient neuron
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compared with wild-type aSyn.81 In addition, the induction of
microglia classical activation by extracellular aSyn also
includes modulation of toll-like receptor expression.77 Extra-
cellular aggregated aSyn added to neuron-glia culture lead to
microglia activation and enhanced dopaminergic neurode-
generation (Figure 3).76 In this study, microglial enhancement
of aSyn-mediated neurotoxicity was shown to be dependent
on phagocytosis of aSyn and activation of NADPH oxidase
with production of reactive oxygen species.76 Recently, direct
activation of the inflammatory response in a microglial cell line
by neuron-derived extracellular aSyn was described.82
A direct effect of extracellular aSyn on microglia activation
in vivo was described in mice injected with human wild-type
aSyn protein into the SN. This treatment induced expression
of pro-inflammatory cytokines, the expression of endothelial
markers of inflammation and microglial activation.78 More-
over, it was demonstrated that the presence of extracellular
aSyn made microglia more susceptible to systemic pro-
inflammatory challenge.78
In addition to the effects on microglia, aSyn has also been
shown to induce astrocytic responses (Figure 3). Transfer of
aSyn from neurons to astrocytes was demonstrated in culture
as well as in vivo in brains of transgenic mice expressing
human aSyn.79 The transmission of neuronal aSyn led to
intra-astrocytic aSyn accumulation and triggered astrocytic
inflammatory response.
Together these different studies provide evidence for the
role of extracellular aSyn in modulating glial function and
neuroinflammation, further supporting the importance of the
study of the mechanisms by which aSyn reaches extracellular
compartments.
Therapeutic Intervention and Future Perspectives
The process of aSyn aggregation is thought to be associated
with both a gain of toxic function and to haploinsufficiency,
by sequestering the wild-type protein and therefore reducing
the amount of functional aSyn available in the cell. Although
accumulating evidence suggests oligomeric forms of aSyn
might constitute the toxic genus, it is still currently unclear
what is the precise form of the toxic aSyn species. Thus, one
possible intervention strategy might be to interfere with aSyn
aggregation in order to reduce the levels of the toxic species.
Recently, aSyn was suggested to exist, physiologically,
as a folded tetramer.83 Moreover, it was shown that the
tetrameric form of aSyn resists aggregation. Interestingly,
the stabilization of the native structure of proteins, preventing
their initial misfolding, is an appealing intervention strategy.
For oligomeric proteins, such as transthyretin, for example,
compounds capable of stabilizing the functional tetrameric
structure hold great potential and are in the process of being
developed.84,85 In light of the recent findings for aSyn, and
despite the current controversy in the field, it is tempting to
speculate that a similar strategy might be envisioned for PD
and other synucleinopathies.
Another line of possible intervention is linked with the
emerging role of extracellular aSyn in disease progres-
sion. Interfering with either the process of aSyn secretion or
with the neuronal uptake of extracellular aSyn might prove
beneficial for stopping or slowing down the propagation of
aSyn pathology in PD and other synucleinopathies. In
addition, removal of aSyn from the extracellular space
might decrease detrimental inflammatory processes. One
promising approach is immunotherapy, as immunization
with human aSyn reduces the accumulation of aggregated
aSyn and reduces neurodegeneration in transgenic mice
overexpressing aSyn.86 Thus, immunotherapy with anti-
bodies promoting the removal of extracellular aSyn species
might delay the progression of the disease.
Altogether, the recent progress in our understanding of
the molecular mechanisms underlying aSyn secretion and
cytotoxicity might pave the way for the development of novel
strategies for therapeutic intervention in PD and other
synucleinopathies.
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